SAB Biotherapeutics Inc. (SABS)

1.56

-0.15 (-8.77%)

At close: Mar 03, 2025, 3:59 PM

1.56

-0.32%

After-hours: Mar 03, 2025, 04:00 PM EST

SAB Biotherapeutics Cash Flow Statement

Table Mode

Year	FY23	FY22	FY21	FY20	FY19
Net Income	-42.19M	-17.14M	-17.14M	20.12M	-8.99M
Depreciation & Amortization	3.75M	1.65M	1.65M	548.18K	323.41K
Stock-Based Compensation	2.42M	2.67M	2.31M	1.3M	371.39K
Other Working Capital	-528.64K	3.83M	3.83M	100K	84.5K
Other Non-Cash Items	8.58M	3.48M	3.48M	-2	1.00
Deferred Income Tax	n/a	n/a	n/a	-2.25K	421.00
Change in Working Capital	2.33M	13.45M	13.45M	-11.95M	-923.37K
Operating Cash Flow	-25.12M	3.76M	3.76M	10M	-9.21M
Capital Expenditures	-197.15K	-10.94M	-10.94M	-12.73M	-608.75K
Acquisitions	n/a	76.39K	n/a	9K	n/a
Purchase of Investments	n/a	n/a	n/a	n/a	n/a
Sales Maturities Of Investments	n/a	n/a	n/a	n/a	n/a
Other Investing Acitivies	44.45K	-76.39K	-10.94M	n/a	n/a
Investing Cash Flow	-152.7K	-10.94M	-10.94M	-12.72M	-608.75K
Debt Repayment	-390.44K	-1.19M	1.54M	-917.88K	n/a
Common Stock Repurchased	n/a	-5.52M	n/a	n/a	n/a
Dividend Paid	n/a	n/a	n/a	n/a	n/a
Other Financial Acitivies	67.16M	76.97K	32.58M	9.9M	n/a
Financial Cash Flow	66.77M	34.12M	34.12M	8.98M	3.68M
Net Cash Flow	41.52M	26.93M	26.93M	6.26M	-6.14M
Free Cash Flow	-25.32M	-7.19M	-7.19M	-2.73M	-9.82M